British drugmaker AstraZeneca has begun testing an antibody-based cocktail for the prevention and treatment of Covid-19, adding to recent signs of progress on possible medical solutions to the disease caused by the novel coronavirus, Reuters reported.
The London-listed firm, already among the leading players in the global race to develop a successful vaccine, has said the study would evaluate if AZD7442, a combination of two monoclonal antibodies (mAbs), was safe and tolerable in up to 48 healthy participants between the ages of 18 and 55 years.
